Skip to main content

Table 5 Efficacy outcomes on day 28 and 42 in the SCD and HbAA groups

From: A randomized trial of artesunate-amodiaquine versus artemether-lumefantrine in Ghanaian paediatric sickle cell and non-sickle cell disease patients with acute uncomplicated malaria

Day 28 SCD HbAA
  Uncorrected PCR-corrected Uncorrected PCR-corrected
ACPR 58 59 57 57
ETF 0 0 0 0
LCF 0 0 0 0
LPF 1 0 0 0
Day 42 SCD   HbAA  
ACPR 55 56 53 54
ETF 0 0 0 0
LCF 0 0 0 0
LPF 2 1 2 1
  1. ACPR = adequate clinical and parasitological response, ETF = early treatment failure, LCF = late clinical failure, LPF = late parasitological failure, SCD = sickle cell disease, HbAA = non-SCD.